Stay updated with breaking news from Nasdaq Dcph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 1,116,913 shares traded hands during trading, a decline of 1% from the previous session’s volume of 1,129,558 shares.The stock last traded at $25.30 and had previously closed at $25.28. Analysts Set New Price Targets DCPH has been the topic […]
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities researchers at Jefferies Financial Group in a note issued to investors on Monday, Benzinga reports. They presently have a $25.60 target price on the stock, down from their prior target price of $26.00. Jefferies Financial Group’s price target would suggest […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) dropped 3.6% during mid-day trading on Monday . The stock traded as low as $14.78 and last traded at $14.79. Approximately 55,852 shares changed hands during trading, a decline of 89% from the average daily volume of 530,911 shares. The stock had previously closed at $15.34. Analysts […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Free Report) – Research analysts at HC Wainwright raised their Q1 2024 EPS estimates for Deciphera Pharmaceuticals in a report issued on Wednesday, February 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.63) per share for the quarter, up from their previous estimate […]
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04, Briefing.com reports. The business had revenue of $48.30 million during the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a […]